Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects - Two prospective, multicentre, open-label, parallel-group volunteer studies

Samantha Abel, Richard Allan, Kuan Gandelman, Konrad Tomaszewskil, David J. Webb, Nolan D. Wood

Research output: Contribution to journalArticlepeer-review

Abstract

Background and objectives: Since little is known regarding the pharmacokinetics of voriconazole in renally impaired patients, two prospective, open-label, parallel-group volunteer studies were conducted to estimate the effect of renal impairment on the pharmacokinetics of oral voriconazole and intravenous voriconazole solubilized with sulphobutylether-beta-cyclodextrin (SBECD), respectively.

Methods: In study A, male subjects with no (n = 6), mild (n = 6), moderate (n = 6) or severe (n = 6) renal impairment received one 200 mg dose of oral voriconazole. Voriconazole plasma levels were periodically assessed until 48 hours post-dose. In study 13, male subjects with no (n = 6) or moderate (n = 7) renal impairment received multiple doses of intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily [day 1] then 3 mg/kg twice daily [days 2-6] followed by a final dose of 3 mg/kg on the morning of day 7) at an infusion rate of 3 mg/kg/h. Voriconazole plasma levels were periodically assessed until 36 hours following the final dose. Pharmacokinetics were determined by non-compartmental methods.

Results: The pharmacokinetics of voriconazole were unaffected in subjects with any degree of renal impairment in both studies. In study B, clearance of SBECD was proportional to creatinine clearance (r(2) = 0.857). Although two subjects had >30% increase in serum creatinine from baseline, these changes did not correlate with SBECD trough levels (r(2) = 0.053). The majority of subjects with moderate renal insufficiency were able to tolerate 7 days of intravenous voriconazole solubilized with SBECD.

Conclusion: These data suggest that renal impairment does not affect the pharmacokinetics of voriconazole. Furthermore, in subjects with moderate renal impairment, there is a strong linear correlation between SBECD clearance and creatinine clearance, and elevated SBECD levels do not necessarily correlate with increased serum creatinine levels (an indicator of worsening renal function).

Original languageEnglish
Pages (from-to)409-420
Number of pages12
JournalClinical drug investigation
Volume28
Issue number7
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects - Two prospective, multicentre, open-label, parallel-group volunteer studies'. Together they form a unique fingerprint.

Cite this